Compounds and compositions for treating hematological disorders
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.
Core Innovation
The disclosure provides cancer treatment methods that administer compound A together with venetoclax. Compound A is identified as an IRAK-4 inhibitor, and venetoclax is used as a BCL-2 inhibitor, specifically venetoclax (ABT-199). The methods are directed to treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, including activated B-cell-like DLBCL (ABC-DLBCL).
The document defines compound A using formulas (I)/(II)/(III) with extensive substituent definitions and includes specific exemplary structures, including Compound A. It further states variable definitions such as A, Y, R1–R3, m, n, and Z1/Z2, and it addresses stereoisomers and pharmaceutically acceptable salts. The described approach is framed as a conjoint administration of an IRAK-4 inhibitor with a BCL-2 inhibitor (venetoclax).
The disclosure states that the combination of compound A and venetoclax provides improved efficacy, including synergistic tumor growth inhibition, compared with either agent alone. It reports example in vivo data in ABC-DLBCL mouse xenograft models (including OCI-Ly10 and SU-DHL-2) showing tumor regression with compound A plus venetoclax. The summary further indicates tolerability as described in the document, and includes discussion of dosing regimens and re-dosing effects.
Claims Coverage
The provided independent claim covers a method of treating DLBCL by administering compound A (an IRAK-4 inhibitor) in conjunction with venetoclax (a BCL-2 inhibitor). The dependent claims further refine the targeted patient subgroup and the DLBCL subtype and include refinements related to comparative efficacy and administration timing.
Conjoint administration for DLBCL treatment
A method of treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, comprising administering compound A and venetoclax, wherein compound A is an IRAK-4 inhibitor.
MYD88 L265P subgroup selection
The method where the subject has an L265P mutation in MYD88.
Activated B-cell subtype DLBCL targeting
The method for an activated B-cell subtype of DLBCL that is an activated B-cell type DLBCL.
Improved efficacy versus separate administration
The method where co-administering compound A with venetoclax provides improved efficacy compared with administering compound A or venetoclax separately.
Simultaneous administration timing
The method performed by administering compound A and venetoclax simultaneously.
Venetoclax timing window relative to compound A
Administering venetoclax within about 5 minutes to about 168 hours before or after administration of compound A.
Across the independent claim and its dependents, the core coverage is a DLBCL treatment method using conjoint administration of an IRAK-4 inhibitor (compound A) with the BCL-2 inhibitor venetoclax, with dependent refinements including MYD88 L265P and activated B-cell DLBCL selection, comparative efficacy versus separate administration, and specific administration timing relationships.
Stated Advantages
Improved efficacy versus administering compound A or venetoclax separately.
Synergistic tumor growth inhibition.
Tumor regression in ABC-DLBCL mouse xenograft models with compound A plus venetoclax.
Documented Applications
Treating Diffuse Large B-cell Lymphoma (DLBCL) in a subject, including activated B-cell-like DLBCL (ABC-DLBCL), using conjoint administration of compound A and venetoclax.
In vivo evaluation in ABC-DLBCL mouse xenograft models, including OCI-Ly10 and SU-DHL-2, showing tumor regression with compound A plus venetoclax.
Interested in licensing this patent?